The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Sequential Therapies for Proliferative Lupus Nephritis
Abstract
BACKGROUND: Long-term therapy with cyclophosphamide enhances renal survival in patients with proliferative lupus nephritis; however, the beneficial effect of cyclophosphamide must be weighed against its considerable toxic effects. METHODS: Fifty-nine patients with lupus nephritis (12 in World Health Organization class III, 46 in class IV, and 1 in class Vb) received induction therapy consisting of a maximum of seven monthly boluses of intravenous cyclophosphamide (0.5 to 1.0 g per square meter of body-surface area) plus corticosteroids. Subsequently, the patients were randomly assigned to one of three maintenance therapies: quarterly intravenous injections of cyclophosphamide, oral azathioprine (1 to 3 mg per kilogram of body weight per day), or oral mycophenolate mofetil (500 to 3000 mg per day) for one to three years. The base-line characteristics of the three groups were similar, with the exception that the chronicity index was 1.9 points lower in the cyclophosphamide group than in the mycophenolate mofetil group (P=0.009). RESULTS: During maintenance therapy, five patients died (four in the cyclophosphamide group and one in the mycophenolate mofetil group), and chronic renal failure developed in five (three in the cyclophosphamide group and one each in the azathioprine and mycophenolate mofetil groups). The 72-month event-free survival rate for the composite end point of death or chronic renal failure was higher in the mycophenolate mofetil and azathioprine groups than in the cyclophosphamide group (P=0.05 and P=0.009, respectively). The rate of relapse-free survival was higher in the mycophenolate mofetil group than in the cyclophosphamide group (P=0.02). The incidence of hospitalization, amenorrhea, infections, nausea, and vomiting was significantly lower in the mycophenolate mofetil and azathioprine groups than in the cyclophosphamide group. CONCLUSIONS: For patients with proliferative lupus nephritis, short-term therapy with intravenous cyclophosphamide followed by maintenance therapy with mycophenolate mofetil or azathioprine appears to be more efficacious and safer than long-term therapy with intravenous cyclophosphamide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
Austin, H. A., Klippel, J. H., Balow, J. E., Le Riche, N. G. H., Steinberg, A. D., Plotz, P. H., & Decker, J. L. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603063141004 · Cited by 1,185
Houssiau, F. A., Vasconcelos, C., D'Cruz, D., Sebastiani, G. D., Garrido, E. D. R., Danieli, M. G., Abramovicz, D., Blockmans, D., Mathieu, A., Direskeneli, H., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10461 · Cited by 1,077
Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis
Chan, T. M., Li, F. K., Tang, C. S. O., Wong, R. W. S., Fang, G. X., Ji, Y. L., Lau, C. S., Wong, A. K. M., Tong, M. K. L., Chan, K. W., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431604 · Cited by 954
Boumpas, D. T., Austin, H. A., Balow, J. E., Vaughan, E. M., Yarboro, C. H., Klippel, J. H., & Steinberg, A. D. (1992) · The Lancet · doi:10.1016/0140-6736(92)92292-n · Cited by 823
Austin, H. A., Muenz, L. R., Joyce, K. M., Antonovych, T. T., & Balow, J. E. (1984) · Kidney International · doi:10.1038/ki.1984.75 · Cited by 718
Gourley, M. F., Austin III, H. A., Scott, D., Yarboro, C. H., Vaughan, E. M., Muir, J., Boumpas, D. T., Klippel, J. H., Balow, J. E., & Steinberg, A. D. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-7-199610010-00003 · Cited by 607
Boumpas, D. T., Austin, H. A., Vaughan, E. M., Yarboro, C. H., Klippel, J. H., & Balow, J. E. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-5-199309010-00003 · Cited by 500
A Controlled Trial of Plasmapheresis Therapy in Severe Lupus Nephritis
Lewis, E. J., Hunsicker, L. G., Lan, S.-P., Rohde, R. D., & Lachin, J. M. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205213262101 · Cited by 473
Steinberg, A. D., & Steinberg, S. C. (1991) · Arthritis & Rheumatism · doi:10.1002/art.1780340803 · Cited by 348
Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans
Dooley, M. A., Hogan, S., Jennette, C., Falk, R., & for the Glomerular Disease Collaborative Network (1997) · Kidney International · doi:10.1038/ki.1997.162 · Cited by 341
Long-term follow-up of patients with lupus nephritis
Appel, G. B., Cohen, D. J., Pirani, C. L., Meltzer, J. I., & Estes, D. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90645-0 · Cited by 278
The natural history of the renal manifestations of systemic lupus erythematosus. 1964.
Pollak, V. E., Pirani, C. L., & Schwartz, F. D. (1997) · Journal of the American Society of Nephrology · doi:10.1681/asn.v871189 · Cited by 248
Baseline characteristics of a multiethnic lupus cohort: PROFILE
Alarcon, G. S., McGwin, G., Petri, M., Reveille, J. D., Ramsey-Goldman, R., Kimberly, R. P., & the PROFILE Study Group (2002) · Lupus · doi:10.1191/0961203302lu155oa · Cited by 214
Baseline characteristics of a multiethnic lupus cohort: PROFILE
Gs, A., McGwin, G., Petri, M., et al. (2002) · Lupus · doi:10.1191/9612332lu155oa · Cited by 153
Cited by
Tsokos, G. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1100359 · Cited by 2,736
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Hahn, B. H., McMahon, M. A., Wilkinson, A., Wallace, W. D., Daikh, D. I., FitzGerald, J. D., Karpouzas, G. A., Merrill, J. T., Wallace, D. J., Yazdany, J., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21664 · Cited by 1,463
Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis
Ginzler, E. M., Dooley, M. A., Aranow, C., Kim, M. Y., Buyon, J., Merrill, J. T., Petri, M., Gilkeson, G. S., Wallace, D. J., Weisman, M. H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043731 · Cited by 1,128
Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis
Appel, G. B., Contreras, G., Dooley, M. A., Ginzler, E. M., Isenberg, D., Jayne, D., Li, L.-S., Mysler, E., Sa[Combining Acute Accent]nchez-Guerrero, J., Solomons, N., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008101028 · Cited by 1,118
Self-citation
Metadata
- Authors
- Contreras, G., Pardo, V., Leclercq, B., Lenz, O., Tozman, E., O'Nan, P., & Roth, D.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-03-04
- Volume
- 350
- Issue
- 10
- Pages
- 971-980
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2094074845
- Cited by
- 818
- References
- 16
- FWCI
- 43.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.